Ukr.Biochem.J. 2024; Volume 96, Issue 2, Mar-Apr, pp. 108-119

doi: https://doi.org/10.15407/ubj96.02.108

Inhibitory action of methylene bisphosphonic acid on metabolic activity and viability of J774A.1 cells

D. O. Labudzynskyi*, E. P. Pasichna, O. I. Krynina, М. M. Veliky

Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv;
*e-mail: labudzinskidmytro@gmail.com

Received: 01 February 2024; Revised: 22 March 2024;
Accepted: 24 March 2024; Available on-line: 30 April 2024

Bisphosphonates (BPs) are primary agents in the current pharmacological arsenal against osteoclast-related bone loss due to osteoporosis, Paget’s disease and bone tumors. Due to the lack of complete understanding of the molecular mechanism of their action in bone tissue and the overlap of key properties between BPs of different generations, integral studies of BPs inhibitory and antiresorptive properties are relevant today. The present work was carried out to establish a comprehensive study of the inhibitory effects of methylene bisphosphonic acid (MBPA) on the mevalonate pathway, metabolic activity and cell death in vitro compared to zoledronic acid (Zol). Farnesyl pyrophosphate synthase activity of MBPA-treated J774A.1 cells was inhibited by 80%, compared with a 79% reduction in Zol-treated samples. The ability of MBPA to decrease the percentage of viable cells in culture is slightly lower compared with Zol. After 24 h of incubation with lowest concentration, the percentage of inhibition of metabolic activity was 10.6 and 25%, respectively. After 48 h, these values were 34.8 and 55.6%, respectively. The inhibitory effects of MBPA and Zol on the intensity of incorporation of radioactively labeled precursor [14C]-acetate to the cholesterol fraction were 76.2 and 59.1%, respectively. In the case of isoprenoid fraction, the inhibitory effects were 40.9% and 51.2%, respectively. MBPA and Zol differently induced apoptosis in the J774A.1 cells culture, increased count of apoptotic cells in 2.4 and 6.3 times, and also increased the number of propidium iodide-positive cells in 7.4 and 19 times, respectively. MBPA and Zol also increased the number of TUNEL-positive cells in macrophage culture in 2.6 and 5 times, respectively. Zoledronate significantly reduced carbonic anhydrase 2 and nuclear factor of activated T-cells 1 gene expression levels compared to the MBPA action. Thus, the use of MBPA in future research and therapy of both cancer and osteoporosis looks promising due to lower cytotoxicity, high efficiency of mevalonate pathway inhibition and the possibility of dosage variation.

Keywords: , , , , , , ,


References:

  1. Ebetino FH, Sun S, Cherian P, Roshandel S, Neighbors JD, Hu E, Dunford JE, Sedghizadeh PP, McKenna CE, Srinivasan V, Boeckman RK, Russell RGG.
    Bisphosphonates: The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use. Bone. 2022;156:116289. PubMed, CrossRef
  2. Huang XL, Liu C, Shi XM, Cheng YT, Zhou Q, Li JP, Liao J. Zoledronic acid inhibits osteoclastogenesis and bone resorptive function by suppressing RANKL‑mediated NF‑κB and JNK and their downstream signalling pathways. Mol Med Rep. 2022;25(2):59. PubMed, PubMedCentral, CrossRef
  3. Nurmi-Lüthje I, Lüthje P. Lessons learned from long-term side effects after zoledronic acid infusion following denosumab treatment: a case report and review of the literature. J Med Case Rep. 2022;16(1):473. PubMed, PubMedCentral, CrossRef
  4. Kim JW, Yee J, Oh SH, Kim SH, Kim SJ, Chung JE, Gwak HS. Machine Learning Approaches for Predicting Bisphosphonate-Related Osteonecrosis in Women with Osteoporosis Using VEGFA Gene Polymorphisms. J Pers Med. 2021;11(6):541. PubMed, PubMedCentral, CrossRef
  5. Riasnyi VM, Apukhovska LI, Velyky NN, Shymanskyy IO, Labudzynskyi DO, Komisarenko SV. Immunomodulatory effects of vitamin D(3) and bisphosphonates in nutritional osteoporosis in rats. Ukr Biokhim Zhurn. 2012;84(2):73-80. (In Ukrainian). PubMed
  6. Kasianenko IV, Pivniuk VM, Dekhtiar TV, Klimenko IO, Oliynichenko GP, Chekhun VF. Efficiency of the new bisphosphonate Mebifon in treatment of patients with bone metastases. Oncology. 2002;4(4):268-270. (In Ukrainian).
  7. Pivniuk VM, Sharykina NI, Dekhtyar TV, Khavych OO, Komisarenko SV, Karlova NP, Oliynychenko GP, Zhebrovska FI, Chekhun VF. Mebifon – an effective domestic bisphosphonic drug. Oncology. 2007; 9(2):1454-150. (In Ukrainian).
  8. Notarnicola M, Messa C, Cavallini A, Bifulco M, TecceMF, Eletto D, Di Leo A, Montemurro S, Laezza C, Caruso MG. Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis. Oncology. 2004;67(5-6):351-358. PubMed, CrossRef
  9. chmidberger JW, Schnell R, Schneider G. Structural characterization of substrate and inhibitor binding to farnesyl pyrophosphate synthase from Pseudomonas aeruginosa. Acta Crystallogr D Biol Crystallogr. 2015;71(Pt 3):721-731. PubMed, PubMedCentral, CrossRef
  10. Folch J, Lees M, Stanley GHS. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226(1):497-509.
    CrossRef
  11. Furse S, Egmond MR, Killian JA. Isolation of lipids from biological samples. Mol Membr Biol. 2015;32(3):55-64. PubMed, CrossRef
  12. Naha PC, Davoren M, Lyng FM, Byrne HJ. Reactive oxygen species (ROS) induced cytokine production and cytotoxicity of PAMAM dendrimers in J774A.1 cells. Toxicol Appl Pharmacol. 2010;246(1-2):91-99. PubMed, CrossRef
  13. Han JM, Song HY, Kim KI, Park WY, Park SH, Byun EB, Byun EH. Polysaccharides from Annona muricata leaves protect against cisplatin‑induced cytotoxicity in macrophages by alleviating mitochondrial dysfunction. Mol Med Rep. 2023;27(1):16. PubMed, PubMedCentral, CrossRef
  14. Marcotorchino J, Romier B, Gouranton E, Riollet C, Gleize B, Malezet-Desmoulins C, Landrier JF. Lycopene attenuates LPS-induced TNF-α secretion in macrophages and inflammatory markers in adipocytes exposed to macrophage-conditioned media. Mol Nutr Food Res. 2012;56(5):725-732. PubMed, CrossRef
  15. Jamil M, Daneshvar A, Nachawati D, El Sharu H, Meysami A. A Rare Presentation of Zoledronate-Induced Systemic Inflammatory Response. Cureus. 2023;15(7):e41524. PubMed, PubMedCentral, CrossRef
  16. Trivedi S, Al-Nofal A, Kumar S, Tripathi S, Kahoud RJ, Tebben PJ. Severe non-infective systemic inflammatory response syndrome, shock, and end-organ dysfunction after zoledronic acid administration in a child. Osteoporos Int. 2016;27(7):2379-2382. PubMed, CrossRef
  17. Fathi-Karkan S, Zeeshan M, Qindeel M, Malekshah RE, Rahdar A, Ferreira LFR. NPs loaded with zoledronic acid as an advanced tool for cancer therapy. J Drug Deliv Sci Technol. 2023;87:104805. CrossRef
  18. Tsoumpra MK, Muniz JR, Barnett BL, Kwaasi AA, Pilka ES, Kavanagh KL, Evdokimov A, Walter RL, Von Delft F, Ebetino FH, Oppermann U, Russell RGG, Dunford JE. The inhibition of human farnesyl pyrophosphate synthase by nitrogen-containing bisphosphonates. Elucidating the role of active site threonine 201 and tyrosine 204 residues using enzyme mutants. Bone. 2015;81:478-486. PubMed, PubMedCentral, CrossRef
  19. Nürenberg G, Volmer DA. The analytical determination of isoprenoid intermediates from the mevalonate pathway. Anal Bioanal Chem. 2012;402(2):671-685. PubMed,CrossRef
  20. Henneman L, van Cruchten AG, Kulik W, Waterham HR. Inhibition of the isoprenoid biosynthesis pathway; detection of intermediates by UPLC-MS/MS. Biochim Biophys Acta. 2011;1811(4):227-233. PubMed, CrossRef
  21. Zhang Q, Yu W, Lee S, Xu Q, Naji A, Le AD. Bisphosphonate Induces Osteonecrosis of the Jaw in Diabetic Mice via NLRP3/Caspase-1-Dependent IL-1β Mechanism. J Bone Miner Res. 2015;30(12):2300-2312. PubMed, PubMedCentral, CrossRef
  22. Moreau MF, Guillet C, Massin P, Chevalier S, Gascan H, Baslé MF, Chappard D. Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. Biochem Pharmacol. 2007;73(5):718-723. PubMed, CrossRef
  23. Streitbuerger A, Henrichs M, Ahrens H, Lanvers-Kaminzky C, Gouin F, Gosheger G, Hardes J. Cytotoxic effect of clodronate and zoledronate on the chondrosarcoma cell lines HTB-94 and CAL-78. Int Orthop. 2011;35(9):1369-1373. PubMed, PubMedCentral, CrossRef
  24. Fiegl M, Juergens M, Hiddemann W, Braess J. Cytotoxic activity of the third-generation bisphosphonate zoledronic acid in acute myeloid leukemia. Leuk Res. 2007;31(4):531-539. PubMed, CrossRef
  25. Niu M, Valdes S, Naguib YW, Hursting SD, Cui Z. Tumor-Associated Macrophage-Mediated Targeted Therapy of Triple-Negative Breast Cancer. Mol Pharm. 2016;13(6):1833-1842. PubMed, PubMedCentral, CrossRef
  26. Kasyanenko IV, Pivnyuk VM, Dekhtyar TV et al. The effectiveness of Mebifon in chemotherapy of patients with breast cancer of various stages. Oncology. 2003;5(3):145-150. (In Ukrainian).
  27. Zhu W, Xu R, Du J, Fu Y, Li S, Zhang P, Liu L, Jiang H. Zoledronic acid promotes TLR-4-mediated M1 macrophage polarization in bisphosphonate-related osteonecrosis of the jaw. FASEB J. 2019;33(4):5208-5219. PubMed, CrossRef
  28. Zhang Q, Atsuta I, Liu S, Chen C, Shi S, Shi S, Le AD. IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws. Clin Cancer Res. 2013;19(12):3176-3188. PubMed, PubMedCentral, CrossRef
  29. Hu C, Zhang M, Wu J, Cao X, Chen L, Yan J, Liang G, Tan J. Bisphosphonate-Modified Functional Supramolecular Hydrogel Promotes Periodontal Bone Regeneration by Osteoclast Inhibition. ACS Appl Mater Interfaces. 2023;15(7):9066-9079. PubMed, CrossRef
  30. Cipriani M, Rostán S, León I, Li ZH, Gancheff JS, Kemmerling U, Olea Azar C, Etcheverry S, Docampo R, Gambino D, Otero L. Multi-target heteroleptic palladium bisphosphonate complexes. J Biol Inorg Chem. 2020;25(3):509-519. PubMed, CrossRef
  31. Kaboudin B, Daliri P, Faghih S, Esfandiari H. Hydroxy- and Amino-Phosphonates and -Bisphosphonates: Synthetic Methods and Their Biological Applications. Front Chem. 2022;10:890696. PubMed, PubMedCentral, CrossRef
  32. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495-516.
    PubMed, PubMedCentral, CrossRef
  33. Kaneko J, Okinaga T, Hikiji H, Ariyoshi W, Yoshiga D, Habu M, Tominaga K, Nishihara T. Zoledronic acid exacerbates inflammation through M1 macrophage polarization. Inflamm Regen. 2018;38:16. PubMed, PubMedCentral, CrossRef
  34. Lu KH, Lu EW, Lin CW, Yang JS, Yang SF. New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma. Pharmacol Ther. 2020;214:107611. PubMed, CrossRef
  35. Yang X, Xu X, Chen J, Wang Q, Wang G, Ai X, Wang X, Pan J. Zoledronic acid regulates the synthesis and secretion of IL-1β through Histone methylation in macrophages. Cell Death Discov. 2020;6:47. PubMed, PubMedCentral, CrossRef
  36. Nakagawa T, Ohta K, Kubozono K, Ishida Y, Naruse T, Takechi M, Kamata N. Zoledronate inhibits receptor activator of nuclear factor kappa-B ligand-induced osteoclast differentiation via suppression of expression of nuclear factor of activated T-cell c1 and carbonic anhydrase 2. Arch Oral Biol. 2015;60(4):557-565. PubMed, CrossRef
  37. Sarhan D, Leijonhufvud C, Murray S, Witt K, Seitz C, Wallerius M, Xie H, Ullén A, Harmenberg U, Lidbrink E, Rolny C, Andersson J, Lundqvist A. Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer. Oncoimmunology. 2017;6(8):e1338238. PubMed, PubMedCentral, CrossRef

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.